Amber Mobley, APRN
Psychiatric/Mental Health · Fort Smith, ARNPI 1750826798
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 340 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 28.2% of the total. Among psychiatric/mental health clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 340 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alkermes, Inc.$745
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$639
- Johnson & Johnson$607
- Axsome Therapeutics, Inc.$503
- Teva Pharmaceuticals USA, Inc.$456
- plus $2K from 8 others
What the payments were for
- Food & beverage$6,28699%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 96 | $1,798 |
| Alkermes, Inc. | 38 | $745 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 43 | $639 |
| Johnson & Johnson | 33 | $607 |
| Axsome Therapeutics, Inc. | 20 | $503 |
| Teva Pharmaceuticals USA, Inc. | 22 | $456 |
| Otsuka America Pharmaceutical, Inc. | 22 | $436 |
| Neurocrine Biosciences, Inc. | 22 | $347 |
| E.r. Squibb & Sons, L.L.C. | 14 | $252 |
| Indivior Inc. | 12 | $231 |
| Lundbeck LLC | 11 | $199 |
| Vanda Pharmaceuticals Inc. | 5 | $113 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$496
- ARISTADA$479
- Auvelity$250
- CAPLYTA$125
- ARISTADA INITIO$120
How this compares
$6,366 in reported general payments places this provider in the 95th percentile of 359 psychiatric/mental health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 34 | $119,665 |
| VraylarCariprazine Hcl | 30 | $38,667 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $24,757 |
| TrintellixVortioxetine Hydrobromide | 18 | $8,756 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 35 | $8,030 |
| Aripiprazole | 49 | $3,975 |
| Lurasidone Hcl | 40 | $3,855 |
| Clozapine | 26 | $2,463 |
| Ziprasidone Hcl | 12 | $1,650 |
| Duloxetine Hcl | 56 | $1,349 |
| Buspirone Hcl | 85 | $1,028 |
| Haloperidol Decanoate | 19 | $1,007 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $850 |
| Oxcarbazepine | 24 | $795 |
| Olanzapine | 48 | $794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $607 | $119,66534 claims |
| AbbVieVraylar | $1,798 | $38,66730 claims |
| Alkermes, Inc.Lybalvi | $745 | $24,75715 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $8,75618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 359 psychiatric/mental health providers in Arkansas.
Other psychiatric/mental health in Fort Smith
- Christopher MilsteadFort Smith$6K
- Lauren AndrewsFort Smith$6K
- Debbie KochFort Smith$4K
- Kellie Berry HertFort Smith$4K
- Kelsey SalleeFort Smith$4K
- Stephanie BohannonFayetteville$32K
- Michael BelinSherwood$30K
- Sarah RamseySearcy$12K
- Mallori LevengoodPine Bluff$11K
- Jennifer PenneFayetteville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.